Hyderabad-based drug major Dr Reddy's Laboratories Limited (DRL), together with its subsidiaries, has launched the recommended public offer to acquire all the issued and outstanding shares of OctoPlus NV, a service-based specialty pharmaceutical company, at an offer price of Euro 0.52 (cum dividend) per share.
The company had announced to acquire OctoPlus Euro 27.39 million in cash. OctoPlus is a Dutch pharma company focused on the development and manufacturing of improved injectable pharmaceuticals based on proprietary drug delivery technologies.
The offer period commences from December 14, 2012, and ends on February 08, 2013, the company said in a filing to the Bombay Stock Exchange (BSE).
Shareholders, including certain members of the boards, holding in aggregate 63.5% of the issued and outstanding ordinary shares of OctoPlus have entered into irrevocable undertakings to tender their shares under the offer, according to the filing.
It had earlier said in a release that the deal would help expand the company’s expertise and scientific capabilities. The acquisition would help the company in ramping up technology capabilities in drug delivery.
Dr Reddy's scrip is currently trading at Rs.1,843.45 on BSE, down 0.74% from the previous close of Rs 1,852.10.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app